Q-omics provides the consensus-scored GGTLC2 profile across patient tissues and cancer cell-line models. GGTLC2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GGTLC2 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, GGTLC2 RNA expression shows 6,949 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and KICH as cancer lineages where GGTLC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GGTLC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GGTLC2 survival associations across molecular data types. GGTLC2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GGTLC2 RNA expression–survival associations across cancer types. High GGTLC2 expression shows unfavorable associations in LIHC, UCEC, UVM and UCS, but favorable associations in KIRP and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for GGTLC2 RNA expression.
This table summarizes GGTLC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for GGTLC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GGTLC2 shows lower tumor expression in KICH, LUSC, LUAD, THCA and KIRC and higher tumor expression in HNSC. The KICH box plot shows higher GGTLC2 RNA expression in normal versus tumor tissue (log2 FC = −0.585, t-test p < 0.001).
This table shows molecular features associated with GGTLC2 in patient tissues and cancer cell lines. In patient samples, GGTLC2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, GGTLC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
